Work

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.5514

Authors: Victoria L. Chiou, Elise C. Kohn, Christina M. Annunziata, Lori M. Minasian, Stan Lipkowitz, Minshu Yu, Nicolas Gordon, Nicole D. Houston, Jung-min Lee

Institutions: National Cancer Institute, National Institutes of Health, Center for Cancer Research

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598553142

Cites:

Cited by: 3

Related to: 10